Bristol-Myers Squibb News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

06.03.18	Bristol-Myers: Opdivo The Only FDA-approved PD-1 Inhibitor With 4-week Dosing (RTTNews)
04.03.18	An Ear To The Pharma: 7 Stocks To Watch This Week (RTTNews)
27.02.18	Biotech Stocks Facing FDA Decision In March (RTTNews)
15.02.18	AMAG Gets FDA Nod, ABMD Hits All-time High, GLMD's NAFLD Trial Flops, NKTR Abuzz (RTTNews)
12.02.18	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY (PR Newswire)
12.02.18	SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bristol-Myers Squibb Company (BMY) & Lead Plaintiff Deadline: April 10, 2018 (PR Newswire)
05.02.18	Bristol-Myers Q4 Results Top View; Meets Primary Endpoint In Lung Cancer Trail (RTTNews)
05.02.18	Bristol-Myers Squibb Phase 3 CheckMate -227 Study Meets Co-primary Endpoint (RTTNews)
05.02.18	Bristol-Myers Squibb Co. Reveals Increase In Q4 Earnings (RTTNews)
16.01.18	The Race To Find A Treatment For NASH (RTTNews)
20.12.17	TARIS And Bristol-Myers Enter Into Clinical Trial Collaboration (RTTNews)
18.12.17	Bristol-Myers Gets Positive CHMP Opinion Recommending Approval Of Yervoy (RTTNews)
08.12.17	New Drugs Approved In November (RTTNews)
28.11.17	Bristol-Myers: EMA To Review Opdivo Plus Yervoy In Expanded Indications (RTTNews)
13.11.17	FDA Nod For BMY's Sprycel, ARNA To Report Data In Q1, MYL Delists From TASE (RTTNews)
11.11.17	First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative... (PR Newswire)
10.11.17	Bistol-Myers: Encouraging Response Observed With Opdivo Plus IDO1 Inhibitor (RTTNews)
10.11.17	Bristol-Myers Says FDA Expands Approval Of Sprycel (RTTNews)
06.11.17	Bristol-Myers Reports Overall Survival Update From Phase 3 CheckMate -025 Study (RTTNews)
30.10.17	EMA Validates Bristol-Myers' Type II Variation Application For Opdivo (RTTNews)
27.10.17	Biotech Stocks Facing FDA Decision In November (RTTNews)
26.10.17	M2Gen® Announces Bristol-Myers Squibb's Participation in ORIEN Avatar™ Research Program (PR Newswire)
26.10.17	Bristol-Myers Squibb Increases 2017 Non-GAAP EPS Guidance - Quick Facts (RTTNews)
26.10.17	Bristol-Myers Squibb Co. Reports 8% Decline In Q3 Bottom Line (RTTNews)
25.10.17	Avis aux médias : Groupe Canaccord Genuity Inc. accès à l'information relative aux résultats du deuxième trimestre de 2018 (PR Newswire)
20.10.17	Bristol-Myers To Present Data Across Serious Liver Diseases - Quick Facts (RTTNews)
17.10.17	ANIK Expands Horizons, FENC Hits Study Goals, IMDZ Abuzz, One More For Opdivo (RTTNews)
16.10.17	Bristol-Myers: Opdivo Shows Encouraging Response, Survival Rates - Quick Facts (RTTNews)
12.10.17	Bristol-Myers Squibb (BMY) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH (PR Newswire)
25.09.17	Infinity Pharma, Bristol-Myers Collaborate; Expands IPI-549 Study (RTTNews)
25.09.17	Opdivo, Keytruda Back In The News, FDA Snubs AGN, EARS Catches Eyes (RTTNews)
22.09.17	AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors (PR Newswire)
22.09.17	Bristol-Myers Reports Approval Of Opdivo For Recurrent Gastric Cancer In Japan (RTTNews)
20.09.17	Le PARK(ing) Day à la Cité multimédia! (PR Newswire)
14.09.17	Stock Score Reports for Bristol-Myers Squibb, Cliffs Natural Resources, Hertz Global Holdings, Nordstrom and Oclaro Inc. (PR Newswire)
14.09.17	Bristol-Myers Partners With Halozyme; Gains Access To ENHANZE Technology (RTTNews)
13.09.17	Breakfast Technical Briefing on Drug Makers Stocks -- AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson (PR Newswire)
11.09.17	New Hope For AZN's Old Drug, More About BMY's Opdivo, IMDZ On Watch (RTTNews)
10.09.17	Bristol-Myers Announces Results From The Phase 3 CheckMate (RTTNews)
08.09.17	Bristol-Myers: Phase 3 Data Reinforce Sustained Survival Benefit Of Opdivo (RTTNews)
07.09.17	Bristol-Myers: Phase 3 Study Of Opdivo Plus Yervoy Met Co-primary Endpoint (RTTNews)
29.08.17	Biotech Stocks Facing FDA Decision In September (RTTNews)
29.08.17	KMDA Slips On AAT Therapy Concerns, ETRM Gains Weight, LJPC On Watch (RTTNews)
28.08.17	Bristol-Myers, Pfizer Report Investigational Eliquis Data - Quick Facts (RTTNews)
28.08.17	Bristol-Myers: Eliquis Shows Lower Risk Of Stroke In NVAF Patient Subgroups (RTTNews)
16.08.17	ALXN's Strengthening Patents, FOLD's Fabry Drug Approved In OZ, VBIV Surges (RTTNews)
10.08.17	Technical Snapshots for These Drug Makers Stocks -- AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson (PR Newswire)
03.08.17	Bristol-Myers Squibb To Acquire IFM Therapeutics - Quick Facts (RTTNews)
02.08.17	FDA Nod For AGIO's IDHIFA, BMY Expands Opdivo Use, OCUL Reduces Headcount (RTTNews)
31.07.17	Biotech Stocks Facing FDA Decision In August (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.62	1.81 %	K V
CieFinRichemont	122.35	0.99 %	K V
Lonza Grp	531.00	0.84 %	K V
Zurich Insur Gr	553.00	0.18 %	K V
Novartis	91.93	0.00 %	K V
ABB	49.54	-0.84 %	K V
Swisscom	504.00	-0.98 %	K V
Sika	228.60	-1.12 %	K V
Holcim	88.42	-1.51 %	K V
UBS Group	27.76	-2.08 %	K V

mehr

26.11.24		Verluste in New York: Dow Jones legt den Rückwärtsgang ein
26.11.24		DAX aktuell: DAX beendet die Dienstagssitzung mit Verlusten
26.11.24		Börse Zürich: SMI letztendlich in Rot
26.11.24		Schwache Performance in Europa: Euro STOXX 50 schlussendlich leichter
26.11.24		Schwache Performance in Frankfurt: LUS-DAX letztendlich in Rot
26.11.24		S&P 500-Wert Pfizer-Aktie: So viel Verlust wäre bei einem Investment in Pfizer von vor einem Jahr angefallen
26.11.24		Dow Jones 30 Industrial-Papier Merck-Aktie: Wäre eine Merck-Investition von vor einem Jahr lukrativ gewesen?
26.11.24		Schwacher Handel in New York: Dow Jones zum Start mit Abgaben

26.11.24

Verluste in New York: Dow Jones legt den Rückwärtsgang ein

26.11.24

DAX aktuell: DAX beendet die Dienstagssitzung mit Verlusten

26.11.24

Börse Zürich: SMI letztendlich in Rot

26.11.24

Schwache Performance in Europa: Euro STOXX 50 schlussendlich leichter

26.11.24

Schwache Performance in Frankfurt: LUS-DAX letztendlich in Rot

26.11.24

S&P 500-Wert Pfizer-Aktie: So viel Verlust wäre bei einem Investment in Pfizer von vor einem Jahr angefallen